Business
Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost
Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered monthly
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered monthly during the initial three-month interventional phase, combined with glutathione in the experimental arm to evaluate potential improvements in ASD symptoms.","length":655,"tagName":"p"},{"type":"text","content":"The 24-month randomized, crossover study targets ~100 children aged 3-12 with confirmed ASD (DSM-5 and ADOS-2 supported). The active arm receives three monthly AdiaVita infusions plus glutathione; the comparator arm starts with glutathione alone, with crossover options later. Primary outcomes include changes in Autism Treatment Evaluation Checklist (ATEC) scores, with close safety monitoring across speech, sociability, sensory awareness, and behavior.","length":455,"tagName":"p"},{"type":"text","content":"This trial builds on promising 2025 results from Adia Med's treatment of five children using a similar protocol. Families reported meaningful symptom improvements, including one child with an ATEC score reduction of over 40 points-indicating substantial gains in key areas. These early, compassionate-use observations drove the launch of this formal, larger-scale study to rigorously assess safety and efficacy.","length":415,"tagName":"p"},{"type":"text","content":"Participation Cost and AccessibilityEnrollment requires a one-time $12,000 fee that covers both Phase One and Phase Two, including all treatments, procedures, and study activities. This fixed fee applies regardless of initial randomization group: children in the glutathione-only arm during Phase One will receive the full three AdiaVita stem cell infusions in Phase Two (crossover), provided they continue to meet safety criteria and study requirements. No monetary incentives are offered. Adia Med cannot fully subsidize costs due to limited capital and has chosen not to seek government grants, which could delay the study by 3-5 years through lengthy applications, reviews,...